Close
Achema middle east
swop processing & packaging

Cancer Vaccine Company DCPrime and Janssen To Collaborate on Potential New Therapy

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Cancer vaccine company DCPrime BV today announced that it has entered into a research and optional license agreement with Janssen Pharmaceuticals Inc. The collaboration has been facilitated in conjunction with the Johnson & Johnson London Innovation Centre where a team of business science and transaction experts are identifying and building novel early-stage collaborations with emerging companies.

Under the agreement Janssen will utilize DCPrime’s DCOne™ technology in feasibility studies for the development of a dendritic cell-based vaccine. Additionally Janssen will have the option to further develop a candidate therapeutic towards regulatory approval.

“DCPrime is always looking for new opportunities for our DCOne technology†said Marcel Zwaal CEO of DCPrime. “We are very excited to be able to work with Janssen and it will enable us to further extend the use our vaccine products.â€

About DCPrime

DCPrime develops off-the-shelf dendritic cell-based vaccines for a broad range of cancer types based on its unique proprietary technology platform DCOneâ„¢. DCOne-based dendritic cell vaccines in some indications loaded with cancer antigens for targeted treatment will be used as standardized therapeutic products. The platform combines the power of dendritic cell-based vaccines with the advantages of allogeneic stimulation of the immune system and the simple logistics of off-the-shelf products. DCPrime has successfully completed a Phase I/IIa study in AML and has developed a commercial scale manufacturing process for DCOne-based vaccines.

 

 

 

Latest stories

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »